Business
Lexaria’s DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study
Blood glucose levels reduced by 19.9% with DehydraTECH-CBDImprovements in kidney function also demonstratedKELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria
About this update from Lexaria Bioscience Corp.
[{"type":"text","content":"Blood glucose levels reduced by 19.9% with DehydraTECH-CBDImprovements in kidney function also demonstratedKELOWNA, BC / ACCESSWIRE / June 16, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the \"Company\" or \"Lexaria\"), a global innovator in drug delivery platforms is pleased to report upon additional findings from its diabetes animal study DIAB-A22-1, and also provide updates on two other applied R&D programs.Diabetes: DIAB-A22-1As announced on March 2, 2023, Lexaria completed initial testing using DehydraTECH-CBD in its diabetes animal model study that produced three positive outcomes including weight loss in obese diabetic-conditioned animals, together with improved triglyceride and cholesterol levels. Following this, Lexaria undertook a further round of analysis to explore additional study outcomes, including the use of an alternate blood glucose assay detection system with higher detection sensitivity than was used in the initial testing round. Using the Antech hexokinase blood chemistry test panel methodology, Lexaria discovered that blood glucose levels were statistically significantly lowered by 19.9 ± 7% in the obese diabetic-conditioned animals treated with the DehydraTECH-CBD 30 mg/Kg dose (yellow bar above) (*p","length":2088,"tagName":"div"}]